Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01943500 · ClinicalTrials.gov registry record
Collection of Blood Specimens for Circulating Tumor Cell Analysis
A clinical trial of Breast Cancer and Prostate Cancer, sponsored by Viatar.
- Completed
- Registry status
- 14
- Enrollment target
- 1
- Study location
NCT01943500: Completed study of Breast Cancer and Prostate Cancer, sponsored by Viatar.
NCT01943500 is a study of Breast Cancer and Prostate Cancer that has completed, run by Viatar. The registered enrollment target is 14 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01943500, a study of Breast Cancer and Prostate Cancer, has completed, sponsored by Viatar.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective: To test the sensitivity of a proprietary novel filtration device designed to capture and concentrate circulating tumor cells (CTCs).
Primary Outcome
Blood samples will be collected from study subjects and analyzed for the number of circulating tumor cells (CTCs) within 96 hours of blood collection.
Conditions Studied
Study Locations (1)
Massachusetts
- Commonwealth Hematology-Oncology, P.C. - Lawrence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-09-30 |
| Est. Completion | 2016-08-26 |
What the finished NCT01943500 record still lists
NCT01943500 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01943500 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01943500 about?
NCT01943500 is a clinical study titled "Collection of Blood Specimens for Circulating Tumor Cell Analysis". Objective: To test the sensitivity of a proprietary novel filtration device designed to capture and concentrate circulating tumor cells (CTCs).
What is the current status of trial NCT01943500?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2013-09-30. Estimated completion is 2016-08-26.
What conditions does trial NCT01943500 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer.
Who is sponsoring clinical trial NCT01943500?
This trial is sponsored by Viatar, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01943500 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01943500's enrollment target sits among peer trials
14 1154th of 1224 higher than 65 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy